Subramaniyam Rajan, MD
Critical Care Medicine · Austin, TXNPI 1922324813
Payments from drug & device makers
What this record shows
This record is dominated by education: $80,101 of the $98,285 with a category attached, or 81.5%. Intuitive Surgical accounts for 98.6% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $49,817, more than ten times the $989 reported in 2022. Among critical care medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $528.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$97K
- GSK$303
- Sanofi$166
- Medtronic$148
- United Therapeutics Corporation$122
- Regeneron Healthcare Solutions, Inc.$101
- plus $514 from 9 others
What the payments were for
- Speaking & faculty fees$5001%
- Travel & lodging$12,33013%
- Food & beverage$5,3545%
- Education$80,10181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 130 | $96,931 |
| GSK | 16 | $303 |
| Sanofi | 10 | $166 |
| Medtronic | 2 | $148 |
| United Therapeutics Corporation | 5 | $122 |
| Regeneron Healthcare Solutions, Inc. | 3 | $101 |
| ERBE USA Inc | 1 | $93 |
| Boehringer Ingelheim | 4 | $82 |
| Insmed, Inc. | 4 | $65 |
| AstraZeneca | 3 | $63 |
| Viatris Specialty LLC | 2 | $60 |
| Mallinckrodt Hospital Products Inc. | 2 | $50 |
| Mylan Specialty L.p. | 2 | $40 |
| Grifols USA, LLC | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$95,723
How this compares
$98,285 in reported general payments places this provider in the 95th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 37 | $470,357 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 202 | $191,358 |
| Spiriva RespimatTiotropium Bromide | 73 | $53,100 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $38,282 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $35,477 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 53 | $33,047 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $26,539 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 275 | $9,402 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $7,538 |
| AlvescoCiclesonide | 23 | $6,920 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $6,117 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $4,852 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $4,204 |
| Arnuity ElliptaFluticasone Furoate | 18 | $3,699 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $82 | $556,504163 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $303 | $264,611328 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $63 | $44,39960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Austin
- William BartekAustin$284K
- Matthew AndersonAustin$79K
- John HinzeAustin$28K
- Steven DavidoffPlano$364K
- Edwin ParsleyHouston$283K
- Hector PayanEl Paso$245K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
- Akinyinka AjelabiKingwood$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.